Evidence map›Paper›PMID 39271151›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Impact of Baseline SARS-CoV-2 Load in Plasma and Upper Airways on the Incidence of Acute Extrapulmonary Complications of COVID-19: A Multicentric, Prospective, Cohort Study.

Tomas O Jensen, Katrina Harper, Shaili Gupta, Sean T Liu, Nila J Dharan, Jason V Baker, Sarah L Pett, Kathryn Shaw-Saliba, Aliasgar Esmail, Minh Q Ho and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tomas O JensenCentre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0398-4431
Katrina HarperDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.
Shaili GuptaDepartment of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA.
Sean T LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nila J DharanKirby Institute, University of New South Wales Sydney, Sydney, New South Wales, Australia.
Jason V BakerDivision of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Sarah L PettThe Medical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom.
Kathryn Shaw-SalibaNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Aliasgar EsmailDivision of Pulmonology, Department of Medicine, Centre for Lung Infection and Immunity, University of Cape Town Lung Institute, Cape Town, South Africa.ORCID 0000-0002-1835-9252
Minh Q HoDepartment of Infectious Diseases, Orlando VA Medical Center, Orlando, Florida, USA.
Eyad AlmasriDepartment of Pulmonology, University of California San Francisco, Fresno, California, USA.
Robin L DewarVirus Isolation and Serology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Jens LundgrenCentre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8901-7850
David M VockDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7M
Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI GRUND, BIRGIT, REILLY, CAVAN S. · 2019 to 2024
$18.0M
National Institute of Allergy and Infectious DiseasesNCI NIH HHS 75N91019D00024NHLBI NIH HHS OT2 HL156812NIAID NIH HHS U01 AI136780NIH HHS 1OT2HL156812-01
6 · The paper itself

Abstract

backgroundExtrapulmonary complications (EPCs) are common in patients hospitalized for coronavirus disease 2019 (COVID-19), but data on their clinical consequences and association with viral replication and systemic viral dissemination are lacking.

methodsPatients hospitalized for COVID-19 and enrolled in the Therapeutics for Inpatients with COVID-19 (TICO) platform trial at 114 international sites between August 2020 and November 2021 were included in a prospective cohort study. We categorized EPCs into 39 event types within 9 categories and estimated their frequency through day 28 and their association with clinical outcomes through day 90. We analyzed the association between baseline viral burden (plasma nucleocapsid antigen [N-Ag] level and upper airway viral load) and EPCs, adjusting for other baseline factors.

resultsA total of 2625 trial participants were included in the study. Their median age was 57 years (interquartile range, 46-68 years), 57.7% were male, and 537 (20.5%) had ≥1 EPC. EPCs were associated with higher day-90 all-cause mortality rate (hazard ratio, 9.6 [95% confidence interval, 7.3-12.7]) after adjustment for other risk factors. The risk of EPCs increased with increasing baseline plasma N-Ag level (hazard ratio, 1.21 per log10 ng/L increase [95% confidence interval, 1.09-1.34]), and upper airway viral load (1.12 per log10 copies/mL increase [1.04-1.19), after adjustment for comorbid conditions, disease severity, inflammatory markers, and other baseline factors. Trial treatment allocation had no effect on EPC risk.

conclusionsSystemic viral dissemination as evidenced by high plasma N-Ag level and high respiratory viral burden are associated with development of EPCs in COVID-19, which in turn are associated with higher 90-day mortality rates.

Indexed as

COVID-19SARS-CoV-2Viral LoadAdaptive Clinical Trials as TopicAdultAgedFemaleHospitalizationHumansIncidenceMaleMiddle AgedProspective StudiescomplicationsCOVID-19extrapulmonarynucleocapsid phosphoproteinSARS-CoV-2 viral load

Identifiers

PMID39271151
PMCPMC11650867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.